DNA extracted from cancer patients' whole blood may contain somatic mutations from
circulating tumor DNA (ctDNA) fragments. In this study, we introduce cmDetect, a …

Abstract Analysis of cell-free DNA using next-generation sequencing (NGS) is a powerful
tool for the detection/monitoring of alterations present in circulating tumor DNA (ctDNA) …

Background Observations of recurrent somatic mutations in tumors have led to identification
and definition of signaling and other pathways that are important for cancer progression and …

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted
54-gene next generation sequencing panel in metastatic solid tumor patients - PMC Back to …

Solid malignancies are often diagnosed at a late stage with dismal prognosis. Even after
cancer is diagnosed, we lack sensitive tools to guide difficult therapeutic decisions such as …

Background: Qualitative and quantitative detection of circulating tumor DNA (ctDNA) is a
liquid biopsy technology used for early cancer diagnosis. However, the plasma ctDNA …

The use of blood-circulating cell-free DNA (cfDNA) as 'liquid-biopsy'is explored worldwide,
with hopes for its potential in providing prognostic or predictive information in cancer …

Circulating cell-free DNA from blood plasma of cancer patients can be used to non-
invasively interrogate somatic tumor alterations. Here we develop MSK-ACCESS (Memorial …

Background Ultra-deep next-generation sequencing of circulating tumor DNA (ctDNA) holds
great promise as a tool for the early detection of cancer and for monitoring disease …

Circulating cell-free DNA (cfDNA) from blood plasma of cancer patients can be used to
interrogate somatic tumor alterations non-invasively or when adequate tissue is unavailable …